Is Heron Therapeutics (HRTX) a Good Investment Now?
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price
Heron Therapeutics Shares Are Trading Higher Following Better-than-expected Q4 Financial Results.
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (HRTX), Milestone Pharmaceuticals (MIST) and Personalis (PSNL)
Strong Week for Heron Therapeutics (NASDAQ:HRTX) Shareholders Doesn't Alleviate Pain of Five-year Loss
Heron Therapeutics Analyst Ratings
Heron Therapeutics Reports Strong 2024 Financial Results
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4
Analysts' Top Healthcare Picks: Heron Therapeutics (HRTX), DENTSPLY SIRONA (XRAY)
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2024 Earnings Conference
Heron Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results.
Heron Therapeutics GAAP EPS of $0.02 Beats by $0.05, Revenue of $40.78M Beats by $3.41M
Express News | Heron Therapeutics Inc: Outlook FY Net Rev $153.0 Mln to $163.0 Mln
Heron Therapeutics | 10-K: FY2024 Annual Report
Heron Therapeutics: District Court Upheld Validity of CINVANTI Patents Which Expire in 2035 >HRTX
Heron Therapeutics | 8-K: Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Express News | Heron Therapeutics Q4 Net Income USD 3.663 Million
Express News | Heron Therapeutics Q4 Operating Expenses USD 26.379 Million
Heron Therapeutics 4Q EPS 2c >HRTX